Exelixis Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$157.2M
Doctors Paid
11,086
Transactions
86,440
2024 Total
$37.1M
Payment Breakdown by Category
Research$126.6M (80.5%)
Consulting$6.7M (4.3%)
Travel$2.2M (1.4%)
Food & Beverage$1.5M (1.0%)
Royalty/License$94,600 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $126.6M | 24,294 | 80.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17.1M | 3,169 | 10.8% |
| Consulting Fee | $6.7M | 649 | 4.3% |
| Travel and Lodging | $2.2M | 6,949 | 1.4% |
| Food and Beverage | $1.5M | 46,577 | 1.0% |
| Grant | $791,639 | 42 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $679,915 | 246 | 0.4% |
| Honoraria | $626,144 | 241 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $618,815 | 217 | 0.4% |
| Education | $136,272 | 4,030 | 0.1% |
| Charitable Contribution | $124,500 | 19 | 0.1% |
| Royalty or License | $94,600 | 7 | 0.1% |
Payments by Type
Research
$126.6M
24,292 transactions
General
$30.6M
62,146 transactions
Ownership
$0
2 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | $27.7M | 5 | 3,448 |
| A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | $10.8M | 0 | 631 |
| A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris | $7.9M | 2 | 1,436 |
| A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | $7.4M | 0 | 893 |
| A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | $4.6M | 0 | 575 |
| A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors | $4.3M | 0 | 372 |
| A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer | $3.1M | 3 | 2,348 |
| A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | $3.0M | 0 | 274 |
| A Randomized Open-Label Phase 3 Study of XL092 plus Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer | $2.8M | 0 | 384 |
| A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk | $2.8M | 0 | 456 |
| A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | $2.7M | 0 | 2,913 |
| A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | $2.4M | 0 | 1,682 |
| A Randomized, Controlled Phase 3 Study of Cabozantinib XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | $2.1M | 0 | 411 |
| A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | $2.0M | 0 | 636 |
| A Randomized, Controlled Phase 3 Study of Cabozantinib XL184 in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | $1.6M | 0 | 370 |
| A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | $1.6M | 0 | 1,104 |
| A Single-arm, two-stage, Phase ll Study of Cabozantinib in patients with refractory metastatic colorectal cancer | $1.3M | 0 | 6 |
| A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors | $1.2M | 0 | 168 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy | $1.2M | 0 | 204 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184 in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy | $1.2M | 0 | 312 |
| A Phase 2 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma | $1.0M | 0 | 7 |
| A Randomized Phase II Trial of Cabozantinib Combined with PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | $960,668 | 0 | 11 |
| A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | $896,012 | 0 | 213 |
| CABOSUN II Cabozantinib versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma | $891,241 | 0 | 23 |
| A Phase II Study of Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas | $826,234 | 0 | 6 |
| A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | $788,096 | 2 | 268 |
| A Phase 3, Randomized, Controlled Study of Cabozantinib XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy | $765,839 | 0 | 186 |
| update | $633,929 | 0 | 2 |
| A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | $632,116 | 0 | 167 |
| A Phase II study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | $609,239 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Prof. Alan Garber, M.d., Ph.d, M.D., PH.D | Internal Medicine | Cambridge, MA | $2.8M | $0 |
| Dr. Stephen Saletan, M.d, M.D | Internal Medicine | New York, NY | $2.7M | $0 |
| Dr. Stephen Sherwin, M.d, M.D | Medical Oncology | San Francisco, CA | $890,066 | $0 |
| Dr. Vincent Marchesi, M.d, M.D | Anatomic Pathology | Guilford, CT | $805,503 | $0 |
| Dr. Mary Spellman, M.d, M.D | Dermatology | San Francisco, CA | $734,686 | $0 |
| Dr. Joseph Hoffman, M.d, M.D | Pulmonary Disease | Park Ridge, NJ | $616,816 | $0 |
| Sue Eckhardt, Md, MD | Medical Oncology | Austin, TX | $379,510 | $0 |
| Dr. John Sarantopoulos, M.d, M.D | Medical Oncology | San Antonio, TX | $360,352 | $0 |
| Dr. Suresh Ratnam, Md, MD | Medical Oncology | Mcallen, TX | $334,176 | $0 |
| Ulka Vaishampayan, Md, MD | Medical Oncology | Ann Arbor, MI | $289,000 | $0 |
| Dr. Maida Taylor, Md, MD | Obstetrics & Gynecology | San Francisco, CA | $279,498 | $0 |
| Dr. Shenhong Wu, M.d, M.D | Medical Oncology | Stony Brook, NY | $239,720 | $0 |
| Dr. Yousuf Gaffar, Md, MD | Hematology & Oncology | Denver, CO | $237,960 | $0 |
| John Berry, Md, MD | Hematology & Oncology | Berwyn, IL | $231,039 | $0 |
| Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD | Medical Oncology | Dallas, TX | $219,223 | $0 |
| Munveer Bhangoo, Md, MD | Medical Oncology | La Jolla, CA | $217,441 | $0 |
| Michael Morse, M.d, M.D | Hematology & Oncology | Durham, NC | $215,359 | $0 |
| Abigail Graeber, Crnp, CRNP | Adult Health | Philadelphia, PA | $211,904 | $0 |
| Grant Lawless, M.d, M.D | Internal Medicine | Thousand Oaks, CA | $195,322 | $0 |
| Dr. Sandy Liu, M.d, M.D | Internal Medicine | Encino, CA | $193,886 | $0 |
| Dr. Nancy Dawson, M.d, M.D | Medical Oncology | Washington, DC | $193,660 | $0 |
| Pierre Gholam, Md, MD | Gastroenterology | Cleveland, OH | $172,035 | $0 |
| Arthur Decillis, M.d, M.D | Internal Medicine | Madison, CT | $154,572 | $0 |
| Dr. Michael Harrison, M.d, M.D | Medical Oncology | Durham, NC | $152,307 | $0 |
| Earle Burgess, Md, MD | Internal Medicine | Charlotte, NC | $144,979 | $0 |
Ad
Top Products
- Cabozantinib $39.9M
- CABOMETYX $39.7M
Associated Products (3)
- Cabozantinib $39.9M
- CABOMETYX $39.7M
- Cabometyx $25.0M
Payment Categories
- Food & Beverage $1.5M
- Consulting $6.7M
- Travel & Lodging $2.2M
- Research $126.6M
- Royalties $94,600
About Exelixis Inc.
Exelixis Inc. has made $157.2M in payments to 11,086 healthcare providers, recorded across 86,440 transactions in the CMS Open Payments database. In 2024, the company paid $37.1M. The top product by payment volume is Cabozantinib ($39.9M).
Payments were distributed across 144 medical specialties. The top specialty by payment amount is Internal Medicine ($8.1M to 1,292 doctors).
Payment categories include: Food & Beverage ($1.5M), Consulting ($6.7M), Research ($126.6M), Travel & Lodging ($2.2M), Royalties ($94,600).
Exelixis Inc. is associated with 3 products in the CMS Open Payments database.